We tested the capacity of each compound to affect the frequency of tumorsphere initiating cells resident in the HCC1954 (human epidermal growth factor receptor 2 (HER2)-overexpressing; basal molecular subtype) and MCF-7 (estrogen receptor positive (ER+); luminal molecular subtype) human breast tumor cell lines. This evidence concerns the gene ERBB2 and breast neoplasm.